Replimune Group Ownership | Who Owns Replimune Group?

Overview ForecastFinancials Chart Transcripts

Replimune Group Ownership Summary

Replimune Group is owned by 31.12% institutional investors, 2.21% insiders, and 66.67% retail investors. Baker bros. advisors lp is the largest institutional shareholder, holding 12.07% of REPL shares. Fidelity Select Biotechnology is the top mutual fund, with 3.07% of its assets in Replimune Group shares.

REPL Ownership Benchmark

Type	Name	% Inst	% Insiders	% Retail
Stock	Replimune Group	31.12%	2.21%	66.67%
Sector	Healthcare Stocks	231.98%	10.74%	-142.72%
Industry	Biotech Stocks	381.47%	10.55%	-292.02%

Institutional Shareholders

Top Institutional Shareholders by Total Shares

Holder	Shares	% Holding	Value
Baker bros. advisors lp	11.05M	12.07%	$46.28M
Price t rowe associates inc /md/	8.31M	9.08%	$34.80M
Blackrock	4.71M	7.08%	$42.42M
Rtw investments, lp	6.40M	6.99%	$26.80M
Blackrock funding, inc. /de	6.07M	6.58%	$59.00M
Fcpm iii services b.v.	4.16M	4.54%	$17.42M
Vanguard group	3.78M	4.10%	$36.70M
State street	3.69M	4.01%	$35.90B
Point72 asset management	3.63M	3.97%	$15.21M
Tang capital management	3.40M	3.72%	$14.25M

Top Institutional Shareholders by % of Total Assets

Holder	Shares	% Assets	Value
Rosalind advisors	1.41M	4.82%	$13.71M
Fcpm iii services b.v.	4.16M	3.48%	$17.42M
Boxer capital management	1.05M	1.40%	$4.40M
Ghost tree capital	450.00K	1.27%	$4.05M
Sofinnova investments	1.81M	1.03%	$16.78M
Boxer capital	1.54M	0.73%	$13.83M
Tang capital management	3.40M	0.55%	$14.25M
Omega fund management	248.67K	0.47%	$1.04M
Readystate asset management lp	2.62M	0.47%	$10.98M
Nan fung group	63.72K	0.45%	$266.98K

Top Buyers

Holder	Shares	% Assets	Change
Rtw investments, lp	6.40M	0.33%	4.33M
Point72 asset management	3.63M	0.03%	2.92M
Readystate asset management lp	2.62M	0.47%	2.43M
Braidwell lp	2.75M	0.34%	2.33M
Boxer capital	1.54M	0.73%	1.54M

Top Sellers

Holder	Shares	% Assets	Change
Redmile group	535.82K	0.22%	-4.13M
Price t rowe associates inc /md/	8.31M	0.00%	-2.51M
Atlas venture life science advisors	-	-	-2.10M
Marshall wace, llp	-	-	-1.87M
Omega fund management	248.67K	0.47%	-1.73M

New Positions

Holder	Shares	% Assets	Change	Value
Boxer capital	1.54M	0.73%	1.54M	$13.83M
Toronto dominion bank	1.37M	0.01%	1.37M	$5.75M
Jefferies financial group	714.23K	0.04%	714.23K	$6.94M
Quinn opportunity partners	650.72K	0.19%	650.72K	$2.73M
Norges bank	459.90K	0.00%	459.90K	$4.14M

Sold Out

Holder	Change
Ifp advisors	-8.00
Nelson, van denburg & campbell wealth management group	-8.00
Global retirement partners	-32.00
Creative financial designs inc /adv	-33.00
Stephens consulting	-35.00

Institutional Ownership Trends

Date	Holdings	Change %	Shares	Change %	Ownership	Change %	Increased Position	Change %	Decreased Position	Change %
Dec 31, 2025	102	-46.32%	28,686,776	-65.39%	31	0.38%	51	-52.34%	33	-31.25%
Sep 30, 2025	187	3.89%	82,873,954	6.75%	90	1.26%	105	25.00%	48	-20.00%
Jun 30, 2025	189	13.17%	80,918,624	7.29%	88	1.08%	86	-2.27%	65	35.42%
Mar 31, 2025	170	6.25%	81,976,905	5.26%	98	1.13%	88	-11.11%	49	48.48%
Dec 31, 2024	91	-38.10%	20,304,371	-70.81%	25	0.33%	55	-30.38%	17	-56.41%

Top Mutual Funds Shareholders

Holder	Shares	% Holding	Change
Fidelity Select Biotechnology	2.53M	3.07%	-
US Small-Cap Growth II Equity Comp	2.44M	2.95%	26.17K
T. Rowe Price New Horizons	2.44M	2.95%	-
State Street® SPDR® S&P® Biotech ETF	2.42M	2.93%	-13.01K
Vanguard US Total Market Shares ETF	2.02M	2.63%	478.00K
Vanguard Total Stock Mkt Idx Inv	1.85M	2.24%	-
iShares Russell 2000 ETF	1.69M	2.05%	1.02M
T. Rowe Price Integrated US Sm Gr Eq	1.60M	1.94%	-
T. Rowe Price Integrated US SmCapGrEq	1.60M	1.94%	-
T. Rowe Price Health Sciences	1.47M	1.78%	-115.46K

Recent Insider Transactions

Date	Name	Role	Activity	Value
Dec 09, 2025	Dhingra Kapil	-	Sell	$32.96K
Dec 02, 2025	Patel Sushil	Chief Executive Officer	Sell	$111.30K
Nov 17, 2025	Sarchi Christopher	Chief Commercial Officer	Sell	$47.39K
Nov 17, 2025	Xynos Konstantinos	Chief Medical Officer	Sell	$65.96K
Aug 15, 2025	Hill Emily Luisa	Chief Financial Officer	Sell	$49.16K

Insider Transactions Trends

Date	Buy	Sell
2026 Q1	-	-
2025 Q4	-	4
2025 Q3	-	1
2025 Q2	-	6
2025 Q1	-	-

REPL Ownership FAQ

Who Owns Replimune Group?

Replimune Group shareholders are primarily institutional investors at 31.12%, followed by 2.21% insiders and 66.67% retail investors. The average institutional ownership in Replimune Group's industry, Biotech Stocks , is 381.47%, which Replimune Group falls below.

Who owns the most shares of Replimune Group?

Replimune Group’s largest shareholders are Baker bros. advisors lp (11.05M shares, 12.07%), Price t rowe associates inc /md/ (8.31M shares, 9.08%), and Blackrock (4.71M shares, 7.08%). Together, they hold 28.23% of Replimune Group’s total shares outstanding.

Does Blackrock own Replimune Group?

Yes, BlackRock owns 7.08% of Replimune Group, totaling 4.71M shares as of Jun 2024. This represents 0.00% of BlackRock's total assets, with a market value of 42.42M$. In the last quarter, BlackRock increased its holdings by 101.23K shares, a 2.19% change.

Who is Replimune Group’s biggest shareholder by percentage of total assets invested?

Rosalind advisors is Replimune Group’s biggest shareholder by percentage of total assets invested, with 4.82% of its assets in 1.41M Replimune Group shares, valued at 13.71M$.

Who is the top mutual fund holder of Replimune Group shares?

Fidelity Select Biotechnology is the top mutual fund holder of Replimune Group shares, with 3.07% of its total shares outstanding invested in 2.53M Replimune Group shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

Customize your own personal stocks lists, views and charts
Choose from hundreds of fields, up to 15 years of history
Conduct deep comparison analysis

Discover trending investment themes
Find your next best investment
Research stocks using tools